Comparing SBRT to RFA for Hepatocellular Carcinoma
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, shared a recent article by Mian Xi on X:
“A writer at Quad Shot News engages in SABR rattling to summarize a recently published randomized clinical trial that compared SBRT to RFA for Hepatocellular Carcinoma (HCC).”
Authors: Mian Xi, Zhoutian Yang, Li Hu, Yizhen Fu, Dandan Hu, Zhongguo Zhou, Mengzhong Liu, Jing Zhao, Jingxian Shen, Qiaoqiao Li, Baoqing Chen, Li Xu, Aiping Fang, Minshan Chen, Shiliang Liu and Yaojun Zhang
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
More posts featuring Drew Moghanaki.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023